melasma
Conditions
Interventions
Sponsors
Eligibility
Inclusion criteria
Inclusion criteria: 1) Adults between the ages of 18 and 60 years; 2) diagnosed as chloasma; 3) no contraindications to tranexamic acid; 4) voluntarily participate in the study and voluntarily sign informed consent.
Exclusion criteria
Exclusion criteria: 1) Pregnant women, lactating women or women who have a pregnancy plan within six months after the end of the study; 2) Women with long-term oral contraceptives; 3) Facial combined with other pigmented abnormal diseases (such as ankle brown cyanosis, vitiligo, Riehl melanosis, etc.); 4) The treatment area has serious diseases such as hemorrhoids, eczema, allergic dermatitis, or scars and excessive hair that have obvious effects on the observation; 5) Participate in other facial cosmetic clinical studies during the study period; 6) Reluctant to stop all whitening cosmetics and take sunscreen measures during the study period; 7) History of systemic systemic diseases (history of thyroid, liver, cardiovascular disease, dyslipidemia, anemia, abnormal blood coagulation mechanism, combined with infectious diseases, psoriasis, diabetes, etc.); 8) Those who have experienced exposure within 1 month before the start of the study; 9) Received any treatment for chloasma (resurfacing, laser, intense pulsed light, drugs, etc.) within 6 months prior to the start of the study.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| the modified melasma area and severity index (mMASI); | — |
Secondary
| Measure | Time frame |
|---|---|
| satisfaction questionnaire; | — |
Countries
China
Contacts
Department of Plastic Surgery, Shanghai Ninth People's Hospital, Shanghai Jiaotong University School of Medicine